Percentage distribution of funding need for implementing DOTS, MDR-TB treatment and ART during DOTS, over regions in 2015.

Notes: The projected total funding need for the three services in 2015 is US$7.9 billion according to the Global Plan to Stop TB 2011–2015 [1]. DOTS is the cost of first-line DOTS for all TB cases including those with MDR-TB and/or coinfected with HIV. MDR is the additional cost for treating those with MDR-TB and ART the additional cost for treating those that are HIV-positive with ART for six months during DOTS.

备注：根据《2011-2015年终结结核病全球计划》[1]，2015年三项结核病防控服务的预计总资金需求为79亿美元。短程督导化疗（Directly Observed Treatment, Short-course, DOTS）指所有结核病病例（包括耐多药结核病（Multidrug-Resistant Tuberculosis, MDR-TB）患者及/或合并人类免疫缺陷病毒（Human Immunodeficiency Virus, HIV）感染者）的一线DOTS治疗成本。MDR指代针对耐多药结核病患者的额外治疗成本，而抗反转录病毒治疗（Antiretroviral Therapy, ART）则指代在DOTS治疗期间为HIV阳性患者提供6个月ART治疗的额外成本。